Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has announced the publication of the Company’s Annual Report and Financial Statements for the year ended 31 December 2025.
The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company’s website: https://cizzlebiotechnology.com
Executive Chair’s Statement
I am pleased to present the Annual Report for the year ended 31 December 2025 which has been a period of strategic advancement and commercial momentum for the Group. The year marked a transitional period as we moved from a development-focused organisation towards commercial execution. Our core mission continues to be the transformation of lung cancer outcomes by enabling earlier detection through a costeffective and scalable blood test that measures the CIZ1B biomarker, which has shown high sensitivity for early-stage disease.
